Input was received from the Gastrointestinal (GI) Society and Crohn’s and Colitis Canada. According to the input, subcutaneous administration for treatment maintenance was seen as appealing and would reduce the need to travel to infusion centres. Patients also described the expected improvements in quality of life and the ability of the drug to provide patients with a more normal and stable life without the effects of CD. The manufacturer’s economic submission captured quality of life while patients receive ustekinumab but did not model administration costs or all adverse events associated with biologics therapy except serious infections.